Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonic Anhydrase 8 (CA8) is a member of the carbonic anhydrase family, but it lacks the typical enzymatic activity due to a key amino acid substitution. Instead, CA8 functions as an allosteric inhibitor of the inositol trisphosphate receptor type 1 (ITPR1), playing a crucial role in regulating intracellular calcium release, particularly in neurons. Mutations in CA8 are associated with neurological disorders characterized by cerebellar ataxia, mental retardation, and dysequilibrium. Overexpression or gene therapy with wildtype CA8 shows promise in correcting pain hypersensitivity by restoring normal calcium signaling via ITPR1 inhibition.
Allosteric inhibition of ITPR1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbonic Anhydrase VIII (None).